Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.

Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B, Thompson C, Li D, Haag-Molkenteller C.

Urology. 2013 Mar;81(3):491-7. doi: 10.1016/j.urology.2012.11.010. Epub 2013 Jan 3.

2.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002. Epub 2011 Jul 13.

PMID:
21798658
3.

An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.

Apostolidis A, Thompson C, Yan X, Mourad S.

World J Urol. 2013 Dec;31(6):1469-74. doi: 10.1007/s00345-012-0984-0. Epub 2012 Nov 18.

PMID:
23160758
4.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.

Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.

PMID:
23608668
5.

Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.

Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C.

J Urol. 2012 Jun;187(6):2131-9. doi: 10.1016/j.juro.2012.01.125. Epub 2012 Apr 12.

PMID:
22503020
6.

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.

Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C.

Neurourol Urodyn. 2013 Nov;32(8):1109-15. doi: 10.1002/nau.22376. Epub 2013 Feb 6.

7.

OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.

Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, Sievert KD, Brin MF, Jenkins B, Thompson C, Lam W, Heesakkers J, Haag-Molkenteller C.

Adv Ther. 2013 Sep;30(9):819-33. doi: 10.1007/s12325-013-0054-z. Epub 2013 Sep 27. Erratum in: Adv Ther. 2014 Feb;31(2):242.

8.

Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity.

Denys P, Dmochowski R, Aliotta P, Castro-Diaz D, Blok B, Ethans K, Aboushwareb T, Magyar A, Kennelly M.

BJU Int. 2017 Jun;119(6):926-932. doi: 10.1111/bju.13795. Epub 2017 Feb 26.

PMID:
28139068
9.

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.

J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14.

PMID:
23246476
10.

Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.

Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD.

Clin Ther. 2013 Apr;35(4):414-24. doi: 10.1016/j.clinthera.2013.02.020. Epub 2013 Mar 20.

PMID:
23522658
11.

Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.

Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P.

Neurourol Urodyn. 2013 Mar;32(3):242-9. doi: 10.1002/nau.22293. Epub 2012 Sep 10.

PMID:
22965657
12.

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.

Chancellor MB, Patel V, Leng WW, Shenot PJ, Lam W, Globe DR, Loeb AL, Chapple CR.

Neurology. 2013 Aug 27;81(9):841-8. doi: 10.1212/WNL.0b013e3182a2ca4d. Epub 2013 Jul 26.

13.

OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.

Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, Patel VD, Zhou J, Thompson C, Kowalski JW.

Eur Urol. 2012 Jul;62(1):148-57. doi: 10.1016/j.eururo.2012.03.005. Epub 2012 Mar 14.

PMID:
22464310
14.

The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.

Chen YC, Kuo HC.

Neurourol Urodyn. 2014 Jan;33(1):129-34. doi: 10.1002/nau.22395. Epub 2013 Mar 12.

PMID:
23494629
15.

Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.

Kennelly M, Dmochowski R, Schulte-Baukloh H, Ethans K, Del Popolo G, Moore C, Jenkins B, Guard S, Zheng Y, Karsenty G; 191622-094 Investigators.

Neurourol Urodyn. 2017 Feb;36(2):368-375. doi: 10.1002/nau.22934. Epub 2015 Nov 24.

PMID:
26607743
16.

Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).

Cruz F, Nitti V.

Neurourol Urodyn. 2014 Jul;33 Suppl 3:S26-31. doi: 10.1002/nau.22630. Review.

PMID:
25042140
17.

Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Cheng T, Shuang WB, Jia DD, Zhang M, Tong XN, Yang WD, Jia XM, Li S.

PLoS One. 2016 Jul 27;11(7):e0159307. doi: 10.1371/journal.pone.0159307. eCollection 2016. Review.

18.

Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF; Botox Detrusor Hyperreflexia Study Team.

J Urol. 2005 Jul;174(1):196-200.

PMID:
15947626
19.

Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.

Sengoku A, Okamura K, Kimoto Y, Ogawa T, Namima T, Yamanishi T, Yokoyama T, Akino H, Maeda Y.

Int J Urol. 2015 Mar;22(3):306-9. doi: 10.1111/iju.12668. Epub 2014 Nov 18.

20.

Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment.

Rovner E, Kohan A, Chartier-Kastler E, Jünemann KP, Del Popolo G, Herschorn S, Joshi M, Magyar A, Nitti V.

J Urol. 2016 Sep;196(3):801-8. doi: 10.1016/j.juro.2016.04.046. Epub 2016 Jun 2.

PMID:
27091236

Supplemental Content

Support Center